NLNK is primed for jump. Marck 2014 high was 50 dollars and recent press could be a windfall. The stock has a twenty five per cent short position with insiders owning 32% and institutions 34%. Through its wholly owned subsidiary, BioProtection Systems Corporation (BPS), today announced a letter contract with the United States Defense Threat Reduction Agency (DTRA) for studies that will bring an Ebola vaccine licensed from the Public Health Agency of Canada closer to human clinical trials. The market cap 720 million and float of 19.84 million shares. "There is an urgent need for a medical countermeasure against the deadly Ebola virus," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink. "This Ebola vaccine has been 100% effective in preventing lethal infection when given to non-human primates before they are infected with the virus. 1) The first is our HyperAcute® immunotherapy technology, which is currently focused on enhancing vaccines for influenza but can be adapted to a number of vaccines. 2) The second technology is based on the yellow fever virus vaccine strain. 3) The third technology is a replication-competent recombinant vesicular stomatitis virus, or rVSV, an advanced vaccine technology developed for the Marburg and Ebola viruses. *** NewLink's HyperAcute immunotherapy platform creates novel biologic products that are designed to stimulate the human immune system to recognize and attack cancer cells. HyperAcute product candidates are composed of human cancer cells that are tumor specific, but not patient specific. These cells have been modified to express alpha-gal, a carbohydrate for which humans have pre-existing immunity. These alpha-gal-modified cells stimulate a rapid and powerful human immune response that trains the body's natural defenses to seek out and destroy cancer cells. *** NewLink's lead product candidate, algenpantucel-L (HyperAcute pancreas), is being studied in a Phase 3 trial (IMPRESS: "Immunotherapy for Pancreatic Resectable cancer Survival Study") under a Special Protocol Assessment with the U.S. Food and Drug Administration. This trial involves up to 722 patients with surgically resected pancreatic cancer. Algenpantucel-L is also being tested in a second Phase 3 study (PILLAR: "Pancreatic Immunotherapy with algenpantucel-L for Locally Advanced non-Resectable"), involving patients with locally advanced pancreatic cancer. *** NewLink has several HyperAcute product candidates focused on other tumor types in various stages of development, including tergenpumatucel-L, which is in an adaptive design, randomized Phase 2B/3 clinical trial currently accruing up to 240 patients with non-small cell lung cancer. Ebola crisis- The warning came just a day the World Health Organization said the scale of the epidemic had been vastly underestimated and that "extraordinary measures" were needed to contain the killer disease. A Month away- The vaccine, called VSV-EBOV, was developed by Canada's National Microbiology Laboratory and is licensed by Ames, Iowa- NewLink is working "around the clock" to start trials, president Nicholas Vahanian said in a telephone interview. "I would personally not hesitate to take that vaccine," said Thomas Geisbert, a virologist at the University of Texas Medical Branch and a developer of the vaccine donated to WHO by the Canadian government. "I've seen it used in many, many non-human primates. Never saw a problem with it." Developing- NewLink also is negotiating with manufacturers to ramp up production, aiming for 10,000 doses within months, Wiley said in a phone interview. Deadly Outbreak
Health officials are weighing the risk of using unproven products as the disease has killed more than 1,000 people and teams of researchers rush to get their vaccines into clinical trials. The outbreak, the worst since the virus was first identified in 1976, has raged through Sierra Leone, Liberia and Guinea and recently reached Nigeria, Africa’s most populous nation. Modupeh Cole, a prominent Sierra Leone doctor treating Ebola patients, died after being infected, the government reported yesterday.
ROLL OUT_ Nancy Kass, a professor of bioethics and public health at the John Hopkins Berman Institute of Bioethics in Baltimore, is among those urging a gradual roll out for the Canadian vaccine